FOR IMMEDIATE RELEASE

Media Contact
Jessica Szramiak, (224) 948-5353
media@baxter.com

Investor Contact
Clare Trachtman, (224) 948-3085

BAXTER INTRODUCES NEW TISSEEL PRIMA SYRINGE AT 2018 AMERICAN ASSOCIATION OF GYNECOLOGIC LAPAROSCOPISTS MEETING

- Next-generation syringe provides physicians with enhanced speed, precision and control during surgery
- Reinforces Baxter’s efforts to offer innovative products to surgeons in the gynecologic specialty that advance patient care and support healing

LAS VEGAS, NOVEMBER 12, 2018 – Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today unveiled the latest design enhancements for its fibrin sealant product, the Tisseel Prima syringe, at the 2018 American Association of Gynecologic Laparoscopists (AAGL) meeting. Attendees can visit Baxter’s booth #807 at the AAGL meeting this week for product demonstrations of the new Prima syringe and the Tisseel 40cm Duplotip Rigid Applicator, along with the rest of Baxter’s portfolio of hemostats and sealants that can be used during gynecological surgeries.

“Launching the Prima syringe illustrates our commitment to continuously advance our proven product portfolio to better meet surgeons’ needs,” said Wil Boren, president of Baxter’s Advanced Surgery business. “We are focused on developing hemostats and sealants that help gynecologists overcome their biggest challenges to promote healing for their patients.”

Baxter’s trusted Tisseel fibrin sealant now features the new Prima syringe, which is a next-generation ergonomic syringe that comes fully assembled and is eight times easier to push\(^1\) than the previous Tisseel syringe. This allows surgeons to have a higher level of precision and control during surgery and has a nearly 17 percent quicker thawing time.\(^2\) Baxter also unveiled its new Tisseel 40cm Duplotip Rigid Applicator, an extended length applicator that is helpful when surgeons need to apply Tisseel to hard to reach areas laparoscopically. Tisseel is the only major brand of fibrin
sealant to offer a complete portfolio of drip and spray applicators, allowing surgeons to select the right tools to address individual patient needs.\textsuperscript{3,4} Gynecologists often perform procedures laparoscopically, such as hysterectomies and myomectomies, which eliminates the need for large abdominal incisions and speeds up the recovery time.

“I’ve experienced the benefits of Tisseel firsthand with my patients and it has become a product that I rely on to help stop bleeding during gynecologic surgeries,” said Kate O’Hanlan, M.D., medical director at the Laparoscopic Institute for Gynecology and Oncology (LIGO) in Portola Valley, California. “When one of my patients suffers a bleed, I want to be able to stop it as quickly as possible. I’m excited that the new Tisseel Prima product will allow me to treat the bleeding more quickly and easily.”

With more than 2,000 publications, including but not limited to clinical studies, case series and reports across specialties—including gynecology—data has shown that Tisseel has been an effective product worldwide for the last 40 years.

About Baxter’s Surgery Portfolio

Baxter is committed to partnering with clinicians to make a meaningful impact on patient care in operating rooms (OR) in nearly 60 countries. Surgeons rely on our hemostats to stop bleeding during surgery, our sealants to close wounds, and our repair patches and biologics to promote healing. We are focused on pioneering innovative and dependable surgical tools and programs that help to improve clinical outcomes while reducing the total cost of care.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Important Safety Information

Tisseel [Fibrin Sealant] Indications
Hemostasis: **Tisseel** is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. **Tisseel** is effective in heparinized patients.

Sealing: **Tisseel** is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies.

Selected Important Risk Information for **Tisseel**

For Topical Use Only. Do not inject **Tisseel** directly into the circulatory system or into highly vascularized tissue. Intravascular application of **Tisseel** can lead to intravascular coagulation, can result in life-threatening thromboembolic events, and can increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients.

Do not use **Tisseel** in individuals with a known hypersensitivity to aprotinin.

Apply **Tisseel** as a thin layer by dripping or spraying using cannula or spray set.

Do not use **Tisseel** for the treatment of severe or brisk arterial or venous bleeding.

Hypersensitivity or allergic/anaphylactoid reactions can occur with the use of **Tisseel**.

This release includes forward-looking statements concerning **Tisseel** (including the **Tisseel Prima syringe and rigid applicator**), including potential benefits associated with its use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

Baxter and **Tisseel** are registered trademarks of Baxter International Inc.

###

1. Baxter Data on File
4. Baxter’s Advanced Surgery Product Catalog